Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: The objective of this study was to compare and evaluate the diagnostic value of serum carbohydrate antigen 125 (CA125) and/or human epididymis protein 4 (HE4) and a panel of novel multiple biomarkers in patients with ovarian tumors to identify more accurate and effective markers for screening ovarian cancer. Methods: Candidate ovarian cancer biomarkers were selected based on a literature search. Dozens of candidate biomarkers were examined using 143 serum samples from patients with ovarian cancer and 157 healthy serum samples as noncancer controls. To select the optimal marker panel for an ovarian cancer classification model, a set of biomarker panels was created with the number of possible combinations of eight biomarkers. Using the set of biomarkers as an input variable, the optimal biomarker panel was selected by examining the performance of the biomarker panel set using the Random Forest algorithm as a non-linear classification method and a 10-fold cross-validation technique. Results: The final selected optimal combination of five biomarkers (CA125, HE4, cancer antigen 15-3, apolipoprotein [Apo] A1, and ApoA2) exhibited a sensitivity of 93.71% and specificity of 93.63% for ovarian cancer detection during validation. Conclusion: Combining multiple biomarkers is a valid strategy for ovarian cancer diagnosis and can be used as a minimally invasive screening method for early ovarian cancer. A panel of five optimal biomarkers, including CA125 and HE4, was verified in this study. These can potentially be used as clinical biomarkers for early detection of ovarian cancer.
Abstract
Objective: The objective of this study was to compare and evaluate the diagnostic value of serum carbohydrate antigen 125 (CA125) and/or human epididymis protein 4 (HE4) and a panel of novel multiple biomarkers in patients with ovarian tumors to identify more accurate and effective markers for screening ovarian cancer. Methods: Candidate ovarian cancer biomarkers were selected based on a literature search. Dozens of candidate biomarkers were examined using 143 serum samples from patients with ovarian cancer and 157 healthy serum samples as noncancer controls. To select the optimal marker panel for an ovarian cancer classification model, a set of biomarker panels was created with the number of possible combinations of eight biomarkers. Using the set of biomarkers as an input variable, the optimal biomarker panel was selected by examining the performance of the biomarker panel set using the Random Forest algorithm as a non-linear classification method and a 10-fold cross-validation technique. Results: The final selected optimal combination of five biomarkers (CA125, HE4, cancer antigen 15-3, apolipoprotein [Apo] A1, and ApoA2) exhibited a sensitivity of 93.71% and specificity of 93.63% for ovarian cancer detection during validation. Conclusion: Combining multiple biomarkers is a valid strategy for ovarian cancer diagnosis and can be used as a minimally invasive screening method for early ovarian cancer. A panel of five optimal biomarkers, including CA125 and HE4, was verified in this study. These can potentially be used as clinical biomarkers for early detection of ovarian cancer.
참고문헌 (30)
- Jemal A, "Cancer statistics, 2008", CA Cancer J Clin, 58, pp.71~96 (2008)
- 하형인, "The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry", Obstetrics & Gynecology Science, 64(5), pp.444~453 (2021), 대한산부인과학회
- Heintz AP, "Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer", Int J Gynaecol Obstet, 95(Suppl 1), pp.S161~S192 (2006)
- Brun JL, "Clinical practice guidelines:presumed benign ovarian tumors--aims, methods, and organization", J Gynecol Obstet Biol Reprod (Paris), 42, pp.710~714 (2013)
- Vaisbuch E, "The role of laparoscopy in ovarian tumors of low malignant potential and early-stage ovarian cancer", Obstet Gynecol Surv, 60, pp.326~330 (2005)
- Marrugo-Ramírez J, "Blood-based cancer biomarkers in liquid biopsy : a promising non-invasive alternative to tissue biopsy", Int J Mol Sci, 19, pp.2877~ (2018)
- Bates SE, "Tumor markers : value and limitations in the management of cancer patients", Cancer Treat Rev, 12, pp.163~207 (1985)
- Holdenrieder S, "Clinically meaningful use of blood tumor markers in oncology", Biomed Res Int, 2016, pp.9795269~ (2016)
- Urban N, "Ovarian cancer screening", Hematol Oncol Clin North Am, 17, pp.989~1005 (2003)
- Buamah P, "Benign conditions associated with raised serum CA-125 concentration", J Surg Oncol, 75, pp.264~265 (2000)
- Hellström I, "The HE4(WFDC2)protein is a biomarker for ovarian carcinoma", Cancer Res, 63, pp.3695~3700 (2003)
- Ahmed AA, "Diagnostic accuracy of CA125and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels", Curr Probl Cancer, 43, pp.450~460 (2019)
- Qing L, "Research progress of ROMA in early diagnosis of ovarian epithelial carcinoma", Adv Mod Biomed Sci, 11, pp.4999~5000 (2011)
- Zhang Z, "An in vitro diagnostic multivariate index assay(IVDMIA)for ovarian cancer : harvesting the power of multiple biomarkers", Rev Obstet Gynecol, 5, pp.35~41 (2012)
- Lee HJ, "A novel detection method of non-small cell lung cancer using multiplexed bead-based serum biomarker profiling", J Thorac Cardiovasc Surg, 143, pp.421~427 (2012)
- Ahn HS, "Serum biomarker panels for the diagnosis of gastric adenocarcinoma", Br J Cancer, 106, pp.733~739 (2012)
- Kim BK, "The multiplex bead array approach to identifying serum biomarkers associated with breast cancer", Breast Cancer Res, 11, pp.R22~ (2009)
- Ho Il Yoon, "Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer", 대한암예방학회지, 21(3), pp.187~193 (2016), 대한암예방학회[DOI]
- Fawzy A, "Tissue CA125 and HE4 gene expression levels offer superior accuracy in discriminating benign from malignant pelvic masses", Asian Pac J Cancer Prev, 17, pp.323~333 (2016)
- Zhuang H, "Co-expression of Lewis Y antigen with human epididymis protein 4 in ovarian epithelial carcinoma", PLoS One, 8, pp.e68994~ (2013)
- Drapkin R, "Human epididymis protein 4(HE4)is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas", Cancer Res, 65, pp.2162~2169 (2005)
- Scambia G, "CA 15-3 serum levels in ovarian cancer", Oncology, 45, pp.263~267 (1988)
- Lotzniker M, "Tumour associated antigens CA 15.3 and CA 125 in ovarian cancer", Int J Biol Markers, 6, pp.115~121 (1991)
- Podzielinski I, "Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer", Cancer Invest, 31, pp.258~272 (2013)
- Zheng X, "Evaluation of HE4 and TTR for diagnosis of ovarian cancer : comparison with CA-125", J Gynecol Obstet Hum Reprod, 47, pp.227~230 (2018)
- Jin C, "Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125", J Ovarian Res, 12, pp.114~121 (2019)
- Sørensen SS, "Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis", Dan Med Bull, 58, pp.A4331~ (2011)
- Clarke-Pearson DL, "Clinical practice. Screening for ovarian cancer", N Engl J Med, 361, pp.170~177 (2009)
- 조혜윤, "Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women", Journal of Korean Medical Science, 30(12), pp.1777~1783 (2015), 대한의학회
- Cui R, "Clinical value of ROMA index in diagnosis of ovarian cancer : meta-analysis", Cancer Manag Res, 28, pp.2545~2551 (2019)